You searched for side effects - Page 50 of 311 - Medivizor
Navigation Menu

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Posted by on Jul 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was associated...

Read More

Is selpercatinib effective in treating brain metastases in RET fusion-positive non-small cell lung cancer?

Is selpercatinib effective in treating brain metastases in RET fusion-positive non-small cell lung cancer?

Posted by on Jul 31, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness selpercatinib (Retevmo) for the treatment of patients with RET fusion-positive non-small cell lung cancer (NSCLC) that has spread to the brain. The authors found that selpercatinib was effective in these patients.  Some background RET mutations are genetic abnormalities that can cause some...

Read More

Is clopidogrel better than aspirin for long-term treatment after cardiac stenting?

Is clopidogrel better than aspirin for long-term treatment after cardiac stenting?

Posted by on Jul 31, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at which antiplatelet drug is better in patients who had percutaneous coronary intervention (PCI). It found that patients who had maintenance treatment with clopidogrel (Plavix) were less likely to suffer from a heart attack, bleeding, stroke, or death over the following 24 months compared to those...

Read More

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva).  This study concluded that this treatment is effective and does not impair the quality of life in these...

Read More

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Posted by on Jul 25, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients. Some background Colorectal cancer (CRC) is one of...

Read More

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Posted by on Jul 25, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the...

Read More

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Posted by on Jul 21, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study characterized the safety and effectiveness of greenlight photo-selective vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that under real-world conditions, GL-PVP provides a safe, effective, and durable BPH treatment option. Some background Lower urinary tract...

Read More

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Posted by on Jul 21, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the benefit of two doses of filgotinib (Jyseleca) with adalimumab (Humira) and placebo, in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX; Otrexup). The data showed that filgotinib reduced RA signs, improved physical activity, prevented structural joint damage progression, and was...

Read More

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Posted by on Jul 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients. Some background Localized prostate cancer...

Read More